LSL Pharma Group Inc. LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.29M | 24.94M | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.29M | 24.94M | -- | -- | -- |
| Cost of Revenue | 26.54M | 20.96M | -- | -- | -- |
| Gross Profit | 3.75M | 3.98M | -- | -- | -- |
| SG&A Expenses | 6.64M | 6.00M | -- | -- | -- |
| Depreciation & Amortization | 189.60K | 38.60K | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.37M | 27.00M | -- | -- | -- |
| Operating Income | -3.08M | -2.07M | -- | -- | -- |
| Income Before Tax | -5.36M | -4.02M | -- | -- | -- |
| Income Tax Expenses | -46.60K | -46.60K | -- | -- | -- |
| Earnings from Continuing Operations | -5.32 | -3.98 | -- | -- | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.32M | -3.98M | -- | -- | -- |
| EBIT | -3.08M | -2.07M | -- | -- | -- |
| EBITDA | -1.16M | -410.80K | -- | -- | -- |
| EPS Basic | -0.04 | -0.03 | -- | -- | -- |
| Normalized Basic EPS | -0.03 | -0.02 | -- | -- | -- |
| EPS Diluted | -0.04 | -0.03 | -- | -- | -- |
| Normalized Diluted EPS | -0.03 | -0.02 | -- | -- | -- |
| Average Basic Shares Outstanding | 492.84M | 481.64M | -- | -- | -- |
| Average Diluted Shares Outstanding | 492.91M | 481.71M | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |